Close Sidebar
Nordic Life Science
Now Reading
Novo Nordisk invests 5.4 billion DKK in expansion of clinical manufacturing facilities
Search for content, post, videos
Search for content, post, videos

Novo Nordisk invests 5.4 billion DKK in expansion of clinical manufacturing facilities

November 23, 2022
1470 Views
Novo Nordisk has announced plans to invest in the expansion of existing facilities in Bagsværd, Denmark. The plans also include the construction of a new plant located in extension of the existing facilities, states the company in its press release. Supply the company's global clinical trials
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.

Malin Otmani

Related Posts

Martin Åmark
November 16, 2020

Xbrane Biopharma has successfully carried out a directed share issue of approximately SEK 200 million at a subscription price of SEK 68.50 per share (the “Directed Share Issue”). The subscription price was determined through an accelerated book-building procedure. A number of Swedish and inteAlready a subscriber Login You have read…

IdeS-Hansa-Medical
May 5, 2015

Novo Nordisk broke ground May 4 on a new 7,500 m2 manufacturing facility in Kalundborg, Denmark. The company is investing 1.5 billion Danish kroner in the facility, which will produce active pharmaceutical ingredients for NovoSeven®and future products for treating hemophilia.  The investment isAlready a subscriber Login You have read all…

Annette Säfholm
April 7, 2020

Gedea Biotech has received its certificate in accordance with ISO 13485: 2016 (Medical devices - Quality management system - Requirements for regulatory purposes). The scope of the certificate includes design, development, marketing, distribution and production of antibiotic-free vaginal tablets Already a subscriber Login You have read all your free articles,…

Anders Holm Photo Stig Jarnes
June 26, 2020

Zelluna Immunotherapy has announced a research collaboration agreement with Lion TCR (Singapore). The collaboration will focus on the development of TCR-NK products for the treatment of virally induced cancers. “This collaboration represents a key milestone for Zelluna and marks an importantAlready a subscriber Login You have read all your free…